Common Drug Review *

Submission Status

Product: Altace HCT

Generic Name: ramipril/hydrochlorothiazide

Manufacturer: Sanofi-Aventis Canada Inc.

Submission Type: New

Date Submission Received: 2006-Oct-26 **Date NOC Issued:** 2006-Jul-13

Targeted CEDAC Meeting: 2007-Feb-21 **Priority Review Granted:** Denied

	Phase	Target Time (Business Days)	Target Date**	Actual CDR Date	Comments
1	Submission Deemed Complete	5	2006-Nov-02	2006-Nov-02	Priority review requested. Priority review denied November 8, 2006.
2	CDR Reviewers' Reports Completed • Reviewers selected and contracted • Literature search and selection completed • Systematic review of clinical data completed • Critical appraisal of pharmacoeconomic (PE) data completed • Clinical and PE reports written • Reports edited and finalized • Reviewers' reports sent to manufacturer	45	2007-Jan-11	2007-Jan-12	Additional information requested December 6, 2006. Additional information received December 7, 2006.
3	Comments from Manufacturer on Reviewers' Reports Received by CDR	7	2007-Jan-22	2007-Jan-23	Due date for manufacturer's comments January 23, 2007.
4	Reviewers' Reply to Manufacturer's Comments Completed	7	2007-Jan-31	2007-Jan-31	
5	CEDAC Brief Completed and Sent to CEDAC Members	5	2007-Feb-07	2007-Feb-07	
6	CEDAC Meeting		2007-Feb-21	2007-Feb-21	
7	CEDAC Recommendation and Reasons for Recommendation Sent to Drug Plans, ACP and Manufacturer	5	2007-Feb-28	2007-Feb-28	
8	Embargo Period*** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation and Reasons for Recommendation	10	2007-Mar-14	2007-Mar-26	Request for extension of Embargo Period received on March 14, 2007. Extension to March 26, 2007 granted. Resubmission submitted March 26, 2007. Work on this review permanently suspended.
9 (a)	Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)	5			
	OR				
9 (b)	Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made)	5			
	OR				
9 (c)	Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request)	25 Depends on Meeting Dates			
10	Final Recommendation sent to Drug Plans, ACP, and Manufacturer	5			

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.
** The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on www.cadth.ca.
*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.